PLx Pharma (PLXP) Stock Forecast, Price & News

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

Is PLx Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma or view top-rated stocks.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for PLx Pharma.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings data on Friday, March, 11th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.04. The biotechnology company had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.05 million. During the same period in the prior year, the business posted ($0.38) earnings per share.
View PLx Pharma's earnings history.

What price target have analysts set for PLXP?

4 Wall Street analysts have issued 12-month price objectives for PLx Pharma's shares. Their forecasts range from $12.00 to $29.00. On average, they anticipate PLx Pharma's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 631.7% from the stock's current price.
View analysts' price targets for PLx Pharma or view top-rated stocks among Wall Street analysts.

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the following people:

• Mr. Michael J. Valentino, Exec. Chairman (Age 68, Pay $393.75k) (LinkedIn Profile)
• Ms. Natasha Giordano, CEO, Pres & Director (Age 62, Pay $884.88k)
• Ms. Rita M. O'Connor CPA, CPA, CFO and Head of Manufacturing & Supply Chain (Age 54, Pay $623.23k)
• Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 69)
• Mr. Tom Long, VP of Manufacturing & Technical Operations
• Ms. Janet M. Barth, VP of Investor Relations & Corp. Communications
• Ms. Joanne Cotignola, VP of Marketing
• Ms. Nicole Godino, National Sales Director
• Mr. Patrick M. Lonergan, Member of Chief Exec. Officer Advisory Group (Age 87)
• Mr. Charles Edmund Sheedy C.F.A., CFA, Member of Chief Exec. Officer Advisory Group (Age 75)

Who are some of PLx Pharma's key competitors?

Some companies that are related to PLx Pharma include Akero Therapeutics (AKRO), Thorne HealthTech (THRN), Aadi Bioscience (AADI), InterCure (INCR), Generation Bio (GBIO), Sernova (SEOVF), Radius Health (RDUS), Biotech Acquisition (BIOT), Dyne Therapeutics (DYN), Theseus Pharmaceuticals (THRX), Lexicon Pharmaceuticals (LXRX), LianBio (LIAN), AC Immune (ACIU), Precigen (PGEN) and Ocular Therapeutix (OCUL).
View all of PLXP's competitors.

What other stocks do shareholders of PLx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).

When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.00%), GW&K Investment Management LLC (1.55%), First Republic Investment Management Inc. (0.65%), Shay Capital LLC (0.32%), State Street Corp (0.29%) and Steward Partners Investment Advisory LLC (0.25%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino, Natasha Giordano and Rita M O'connor.
View institutional ownership trends for PLx Pharma.

Which institutional investors are selling PLx Pharma stock?

PLXP stock was sold by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Vanguard Group Inc., Simplex Trading LLC, Qube Research & Technologies Ltd, UBS Group AG, Ground Swell Capital LLC, and GW&K Investment Management LLC.
View insider buying and selling activity for PLx Pharma or view top insider-selling stocks.

Which institutional investors are buying PLx Pharma stock?

PLXP stock was acquired by a variety of institutional investors in the last quarter, including Shay Capital LLC, MBL Wealth LLC, Shufro Rose & Co. LLC, HAP Trading LLC, Clearline Capital LP, Group One Trading L.P., Private Advisor Group LLC, and Commonwealth Equity Services LLC. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, Natasha Giordano, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma or or view top insider-buying stocks.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $2.87.

How much money does PLx Pharma make?

PLx Pharma has a market capitalization of $79.04 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46.13 million in net income (profit) each year or ($2.710010) on an earnings per share basis.

How many employees does PLx Pharma have?

PLx Pharma employs 16 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is www.plxpharma.com.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at (973) 409-6541, via email at [email protected], or via fax at 713-842-3052.